Here are five insights:
1. The brokerage presently has a $0.25 price objective on the stock.
2. Zacks Investment Research’s price target would indicate a potential upside of 34.41 percent from the stock’s current price.
3. Cytori Therapeutics discovers and develops proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue.
4. The company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery.
5. Cytori developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will improve the speed in which personalized cell-based therapies can be delivered to patients.
More articles on devices and implants:
FDA recalls Brainlab’s neurosurgery device: 5 key points
Medtech sells 2 ROSA Brain robots in US: 3 quick notes
VENUS meniscus implant trial underway at Duke University Medical Center — 6 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
